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Abstract
There are limited community-based data on the 
burden of influenza and influenza-like illnesses 
during pregnancy to inform disease surveillance 
and control. We aimed to determine the incidence 
of medically-attended respiratory illnesses (MARI) 
in pregnant women and the proportion of women 
who are tested for respiratory pathogens at these 
visits. We conducted a nested retrospective cohort 
study of a non-random sample of women aged 
18 years or over who had a live birth in maternity 
units in Brisbane, Queensland, from March 2012 
to October 2014. The primary outcomes were 
self-reported doctor visits for MARI and laboratory 
investigations for respiratory pathogens. Descriptive 
analyses were performed. Among 1,202 par-
ticipants, 222 (18.5%, 95%CI 16.3%–20.7%) 
self-reported MARI during their pregnancy. Of 
those with a MARI, 20.3% (45/222) self-reported 
a laboratory test was performed. We were able to 
confirm with health service providers that 46.7% 
(21/45) of tests were undertaken, responses from 
providers were not received for the remainder. Whilst 
one in 5 women in this population reported a MARI 
in pregnancy, only 3.7% (45/1,202) reported a 
clinical specimen had been arranged at the consul-
tation and the ability to validate that self-report was 
problematic. As the focus on maternal immunisation 
increases, ascertainment of the aetiological agent 
causing MARI in this population will be required and 
efficient and reliable methods for obtaining these 
data at the community level need to be established. 
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Introduction
Influenza is a global public health issue affecting 
both human life and economies in our ever-increas-
ingly interconnected world.1 Some groups in society 
are at higher risk of getting influenza; infants, the 
elderly, and people with certain chronic medical 
conditions.2 Pregnant women are particularly sus-
ceptible to serious consequences from influenza 
infection,3 particularly during pandemics.4 Reasons 
for this are linked to the number of changes that 
occur to a woman’s body during pregnancy, which 
may put pregnant women at higher risk of complica-
tions from influenza (e.g. changes to lung function, 
increased cardiac output, increased oxygen con-
sumption, and impairments to the innate and adap-
tive immune response).5–7 Consequently, the World 
Health Organization recommends that pregnant 
women be given the highest priority for influenza 
vaccine in countries that are initiating or expanding 
a seasonal influenza program.8
While data on hospitalisations for influenza dur-
ing pregnancy are important, few studies have 
identified the incidence of medically-attended 
respiratory illnesses (MARI) during pregnancy 
at the primary health care level. Fewer still have 
reported the proportion of these women who have 
laboratory investigations performed to identify 
the aetiological agent. This lack of data limits the 
ability to accurately assess the burden of influenza 
during pregnancy and the likely effectiveness 
of interventions, such as influenza vaccination, 
aimed at preventing disease.
The objective of this study was to investigate the 
incidence of MARI during pregnancy in women in 
Brisbane, Queensland. A secondary objective was 
to identify the proportion of these women who had 
a laboratory test performed to identify an aetiologi-
cal agent.
Methods
This study was part of an ongoing broader 
prospective cohort study (the FluMum Study)9 
investigating the effectiveness of influenza vac-
cine during pregnancy in preventing laboratory 
confirmed influenza in infants across 6 Australian 
capital cities. Women in Brisbane maternity units 
within 6 participating hospitals (public and/or pri-
vate) were approached for recruitment by trained 
research staff, prior to hospital discharge. The 
selected hospitals included the 2 large tertiary pub-
lic maternity units in inner Brisbane and 4 units 
(3 private, 1 public) in suburbs more than 10 km 
from the city centre.
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Women were eligible for inclusion if they were: 
aged 18 years or over at the time of written informed 
consent, willing and able to adhere to all protocol 
requirements, had sufficient verbal English to 
permit questionnaire completion, and had given 
birth to a live infant. Women were excluded if they 
planned to move overseas before the infant reached 
6 months of age.
At enrolment, a detailed questionnaire was 
completed that collected data on self-reported 
influenza and pertussis vaccination, self-reported 
maternal medical and obstetric history and socio-
demographic indicators. MARIs were determined 
by asking the participant whether, during her 
pregnancy, did she ever have a respiratory illness 
with symptoms like fever, chills, cough, aches and 
pains, that caused her to see a doctor. If yes, par-
ticipants were asked whether a test was performed 
at the visit (nose, throat or blood specimen) but 
they were not specifically asked if the test was for 
influenza or other respiratory pathogens. If a test 
was reported, this was validated by contacting the 
relevant healthcare provider. Three to five attempts 
were made by telephone, email and/or facsimile to 
confirm the test and obtain a diagnosis. Similar 
attempts were made to confirm self-report of 
influenza vaccination during and in the 12 months 
prior to the pregnancy.
We analysed data collected on enrolment from 
the 1,202 women recruited at the Brisbane site 
for the years 2012–2014. The primary endpoint 
was participant-reported attendance at a medical 
practitioner for a respiratory illness during 
pregnancy. The secondary endpoints were a) the 
participant reported clinical specimens collected 
for laboratory investigations at these visits, and 
b) the healthcare provider confirmation of those
laboratory investigations.
The study was approved by the Royal Brisbane 
and Women’s Hospital Human Research Ethics 
Committee (HREC/12/QRBW/85), the Mater 
Mothers Human Research Ethics Committee 
(2012–16), and The University of Queensland 
Medical Research Ethics Committee (2012000180).
Data analysis
The primary analysis was the proportion of 
women who reported a MARI during the 
pregnancy and presented with its 95% 
confidence interval (CI). Secondary analyses 
were the proportion of women who reported a 
test done and of those, the propor-tion that were 
confirmed by the health service pro-vider. 
Descriptive analyses were performed using 
Stata SE V12 (StataCorp, Texas, USA), 
including producing proportions and means 
with 95% CIs, and medians with interquartile 
ranges.
Results
Participant characteristics
Between March 2012 and October 2014, 1,713 
women were screened and 1,202 (70.2%) were 
enrolled into the FluMum study in Brisbane. The 
mean age was 31.5 years (95% CI 31.3–31.8), 2% 
(23/1,196) identified as Aboriginal and/or Torres 
Strait Islander and 698 (58.1%) were recruited 
through public hospitals. More than half of the 
women for whom data were available (947/1,194, 
79%) were in paid employment during their 
pregnancy; the majority of these being in full-
time employment (568, 60%). Approximately 
half (515/1,035, 49%) had completed a university 
degree or higher and approximately 8% of women 
(93/1,195) had smoked during their pregnancy. Of 
the 1,196 women for whom data were available, 340 
(28.4%) self-reported a pre-existing health condi-
tion such as heart disease, respiratory conditions, 
immunosuppressive conditions, cancer or diabetes, 
or a history of pneumonia requiring hospitalisa-
tion in the past 12 months.
Medically attended respiratory illnesses 
during pregnancy
Overall, 222 of 1,202 women (18.5%, 95% CI, 
16.3%–20.7%) reported a respiratory illness that 
caused them to visit a health practitioner during 
their pregnancy. Of these, 39 women reported 
2 episodes, eight reported 3 episodes, and two 
reported 4 episodes. Forty-five (20.3%, 95% CI 
15.0%–25.6%) of the 222 women with a MARI 
reported that a clinical specimen was collected 
at the time (nose swab n=15, and/or throat swab 
n=10, and/or a blood test n=35). No tests were 
reported in episodes subsequent to the initial pres-
entation. Seventy-two (21.2%) of the 340 women 
with a self-reported pre-existing health condition 
reported a MARI during their pregnancy and 
22 (30.6%) of these women reported they had a test 
done.
Despite multiple attempts to secure information 
from providers, confirmation of the test request 
was obtained in 21 (46.7%) episodes. Of the con-
firmed episodes in which a blood test was taken 
(n=13), 7 providers reported the bloods were not 
tested for respiratory viruses. This information was 
not provided for the remaining 6 episodes.
Discussion
Influenza is an important cause of morbidity 
during pregnancy5 but the lack of systematic 
surveillance for disease during pregnancy at the 
community level limits the ability to reliably esti-
mate the burden of disease and the effectiveness 
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of interventions, particularly vaccination. This 
study had identified that almost one in 5 women 
will present to a health care provider during their 
pregnancy for a respiratory illness. Collection of 
clinical specimens during the visit is reported but 
is difficult to confirm. This leads to doubts about 
the reliability of those reports with respect to test-
ing for respiratory pathogens.
There are limited comparable data with which to 
compare the MARI incidence in our study given 
differences in study designs, study populations, 
and the case definitions used for respiratory illness 
and/or influenza-like illness. In a randomised 
controlled trial of inactivated influenza vaccine in 
HIV-negative pregnant women in South Africa 
that employed active surveillance for respiratory 
illnesses,10 17.2% (95% CI 14.9–19.6) of women in 
the control group reported an influenza-like ill-
ness in the period from the time of vaccination to 
up to 24 weeks post-birth of the infant; 65.2% (95% 
CI 62.2–68.1) reported having any respiratory ill-
ness.10 The incidence of illness during pregnancy 
only was not reported. In a cohort study that used 
administrative datasets, Lindsay et al11 reported 8% 
of 8,323 healthy (no underlying chronic conditions) 
pregnant and post-partum women in Washington, 
United States of America, experienced an influ-
enza-like episode that resulted in health-care use 
(total person weeks of observation = 301,778).11
Blood was the predominant specimen women 
reported as being collected. This is unusual given 
there are few clinical indications for serology in 
acute, uncomplicated respiratory illness at the com-
munity level.12 For those who reported a MARI 
episode, we asked “thinking now about the 1st epi-
sode of respiratory illness during your pregnancy 
that caused you to see a doctor, can you tell me the 
tests done?” We then sought further information 
on who had done the test, the diagnosis, gestational 
age at the time of the test and the treating doctors 
contact details. We also sought similar information 
for each subsequent MARI. Whilst we made refer-
ence to episodes of respiratory illness, it is possible 
that there may have been some misunderstanding 
or uncertainty for participants such that the infor-
mation provided may not have directly related to 
specimens collected at a MARI presentation that 
were specifically for a respiratory diagnosis. This is 
partially supported by the number of reports from 
providers stating bloods were not tested for respira-
tory viruses.
The difficulties encountered in confirming the 
test with the health care provider is problematic 
for influenza surveillance and control in this 
population and for estimating the effectiveness of 
maternal influenza and/or pertussis vaccination 
during pregnancy at the population level, particu-
larly in non-pandemic periods. With the exception 
of hospitalised cases, there are limited population-
based data on both the burden of influenza and 
the effectiveness of influenza vaccination during 
pregnancy. This lack of data is recognised as a 
contributing factor towards determining the real 
risk of influenza associated with pregnancy.13, 14 
Such data would enhance public health policy rec-
ommendations and facilitate discussions between 
health care providers and pregnant women on the 
risks of influenza and why the vaccine is recom-
mended in pregnancy.
This study has some limitations that necessitate 
caution in interpreting the findings. The FluMum 
study9 population is derived from English speaking 
women giving birth to a live infant in metropolitan 
maternity units and may not be representative of 
non-English speaking women and those with high 
risk pregnancies and adverse pregnancy outcomes, 
nor of women in rural and remote areas where 
access to health care and the viability of specimen 
collection, transport, and processing for respira-
tory illnesses may differ. While the proportion of 
Aboriginal and Torres Strait Islander women 
enrolled in the study was low (1.7%), it does approx-
imate the 2011 estimated resident Indigenous 
population of the greater Brisbane region (2.0%).15 
Further possible selection and measurement biases 
that may be affecting our findings are potential 
differences between vaccinated and unvaccinated 
women that would influence their decision to 
participate in the study and their recall of MARI. 
Finally, as data were collected retrospectively, mis-
classification due to poor recall may have occurred 
resulting in an over– or under-estimation of MARI 
frequency and of testing for MARI.
MARI during pregnancy is not uncommon yet 
the investigation of these illnesses to determine 
an aetiological agent is infrequent. While labora-
tory investigation of all community-based MARI 
during pregnancy may be unwarranted clinically, 
sentinel surveillance of these events in sites repre-
sentative of Australian pregnant women would be 
a useful contribution to further understanding the 
risk and outcomes of influenza during pregnancy. 
Such surveillance would provide more comprehen-
sive estimates of influenza vaccine effectiveness to 
inform public health policy.
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